{
    "nctId": "NCT06610539",
    "briefTitle": "PAS 1ml Magtrace\u00ae for Sentinel Lymph Node Biopsy in Breast Cancer Patients",
    "officialTitle": "A Prospective Open Label Study of Patient Reported Outcome Measures and Efficacy Following the Use of 1ml Magtrace\u00ae for Sentinel Lymph Node Biopsy in Breast Cancer Patients Undergoing Lumpectomy",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 184,
    "primaryOutcomeMeasure": "Frequency of Magtrace-related skin discoloration as a proportion of patients receiving Magtrace, overall and by sub-sample",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient is willing and able to give informed consent for participation in the study\n* Patient is aged 18 years or older at the time of consent\n* Patients undergoing planned breast conserving surgery (for example, lumpectomy or partial mastectomy) and SLNB with Magtrace\n\nExclusion Criteria:\n\n* The patient is pregnant or lactating\n* The patient has had prior breast radiation to the ipsilateral breast\n* The patient has clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes\n* The patient has recevied a Feraheme (ferumoxytol) injection within the past 6 months\n* The patient has intolerance or hypersensitivity to iron or dextran compounds or to Magtrace\n* The patient has iron overload disease\n* The patient has discoloration on the breast (such as tattoo, birthmark, tanning, rash etc.), that in the Investigator's opinion, could impact the clinical trial results, specifically the assessment of any skin discoloration, or plans to have a tattoo on the breast post-operatively.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}